BioNTech News and Activities

BioNTech is a company listed under the stock ticker BNTX (DE).

BioNTech has a direct presence in 3 countries.

BioNTech has 3 subsidiaries including BioNTech IMFS, BioNTech US and InstaDeep.

They are in:

• Biotechnology75%
• Software25%

Acquisition, funding and merger involving BioNTech.

• BioNTech has acquired CureVac (posted on December 22 2025).
• BioNTech has just announced a $95 Million fundraising (posted on October 16 2025).
• BioNTech has announced the acquisition of CureVac  (posted on June 12 2025).
• BioNTech has just announced a $145 Million fundraising (posted on June 5 2024).
• See more news about BioNTech Hide news involving BioNTech

View the org chart displaying its 75 main executives

Most searched biographies at BioNTech

• Ugur Sahin, Chief Executive Officer
• Ulrich Wandschneider, Director
• Nicola Blackwood, Director

Popular executive movements at BioNTech

• Kylie Jimenez will join the company as Chief People Officer and Director on Mar. 1, 2026  (posted on January 30 2026).

Create your alert
to follow the executive moves at BioNTech.

BioNTech has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by BioNTech

• Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design | BioNTech
• BioNTech to Report Second Quarter 2022 Financial Results and Operational Update on August 8, 2022 | BioNTech
• Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 Adapted Bivalent Vaccine Candidate | BioNTech
• Pfizer and BioNTech Submit a Variation to EMA for the Vaccination of Children Ages 6 Months to less than 5 Years with COMIRNATY® | BioNTech
• Pfizer and BioNTech Announce U.S. FDA Approval of their COVID-19 Vaccine COMIRNATY® For Adolescents 12 through 15 Years of Age | BioNTech
• Statement on Patent Infringement Lawsuit in Germany | BioNTech
• Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine | BioNTech
• Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron | BioNTech
• BioNTech Receives Priority Medicines (PRIME) Designation from EMA for Enhanced Regulatory Support of CAR-T Candidate BNT211 in Testicular Cancer | BioNTech
• BioNTech Starts Construction of First mRNA Vaccine Manufacturing Facility in Africa | BioNTech
• View more press releases Close

Social media about BioNTech

• BioNTech on Wikipedia, Google News & Yahoo Finance
• BioNTech on LinkedIn, X (Twitter) & YouTube